论文部分内容阅读
目的：比较普伐他汀与多烯康治疗高脂血症的疗效与安全性。方法：高脂血症６０例，随机分为２组。普伐他汀组３０例（男性１６例，女性１４例；年龄５８±ｓ１１ａ）采用普伐他汀１０～２０ｍｇ，ｐｏ，ｑｎ×６ｍｏ；多烯康组３０例（男性１８例，女性１２例；年龄６０±１０ａ）采用多烯康胶丸３粒（０．４５ｇ／粒），ｐｏ，ｔｉｄ×６ｍｏ。结果：普伐他汀组总胆固醇、三酰甘油、低密度脂蛋白胆固醇均显著下降（Ｐ＜０．０１），总有效率依次为９０％，５３％，９３％；多烯康组下降均不显著；２组均无明显不良反应。结论：普伐他汀为一安全的、且降脂疗效优于多烯康的药物。
Objective: To compare the efficacy and safety of pravastatin and docetaxel in the treatment of hyperlipidemia. Methods: 60 cases of hyperlipidemia were randomly divided into two groups. 30 cases of pravastatin group (16 males and 14 females; age 58 ± s11a) were treated with pravastatin 10 ~ 20mg, po, qn × 6 months; 30 cases of docetaxel (18 males and 12 females; age 60 ± 10a) with polyenecan capsules 3 (0.45g / tablets), po, tid × 6mo. Results: The total cholesterol, triglyceride and low density lipoprotein cholesterol in pravastatin group were significantly decreased (P <0.01), the total effective rates were 90%, 53%, 93% Significant; 2 groups had no obvious adverse reactions. Conclusions: Pravastatin is a safe and lipid-lowering drug superior to doeconazole.